AbbVie Inc. (ABBV) Presents Data on Fixed-Duration Venetoclax-Based Combination

AbbVie Inc. (NYSE:ABBV) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now.

On June 12, 2026, AbbVie Inc. (NYSE:ABBV) announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association 2026 Congress in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia showed that venetoclax plus obinutuzumab significantly improved progression-free survival compared with chlorambucil plus obinutuzumab. After a median follow-up of 9.2 years, median progression-free survival was 6.4 years for venetoclax plus obinutuzumab versus 3.2 years for obinutuzumab plus chlorambucil.

On May 29, 2026, AbbVie Inc. (NYSE:ABBV) announced that the European Commission authorized an expanded label for Venclyxto to include use in combination with acalabrutinib and with ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia. AbbVie said the all-oral, fixed-duration combination regimens support current standards of care and provide additional targeted oral medication options in the first-line setting, including the potential for time off treatment. The authorization extends to European Union Member States, as well as Iceland, Norway, and Liechtenstein.

AbbVie Inc. (ABBV) Presents Data on Fixed-Duration Venetoclax-Based Combination

On May 27, 2026, AbbVie Inc. (NYSE:ABBV) announced that the FDA approved DECNUPAZ, or pivekimab sunirine-pvzy, for adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options. The approval was supported by data from the Phase 1/2 CADENZA trial. In newly diagnosed BPDCN patients, DECNUPAZ showed a composite complete response rate of 69.7% with a median duration of response of 9.7 months, while relapsed or refractory patients had a composite complete response rate of 15.7% with a median duration of response of 9.2 months.

AbbVie Inc. (NYSE:ABBV) researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1